One of the biggest sensations fueling the healthcare space right now is the medication class of glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with the term "GLP-1," you've ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Researchers ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated ...

Eli Lilly’s performance is riding on the success of GLP-1 weight loss and Alzheimer’s treatments. It is especially true for its GLP-1 drugs, which have led to massive gains, with more to come.

We recently published a list of 10 Best-Performing S&P 500 Stocks in the Last 3 Years. In this article, we are going to take a look at where Eli Lilly (NYSE:LLY) stands against other best performing S ...

That’s where GlucoBoost GLP-1 Booster comes into play. This innovative supplement has garnered attention for its natural approach to weight loss, appealing to those who prefer avoiding synthetic ...

New research shows a marked decline in weight-loss surgeries as GLP-1 meds like Wegovy or Zepbound surge in popularity Bariatric surgeries fell by more than a quarter between 2022 and 2023, as ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class ...

Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds By Ernie Mundell HealthDay Reporter FRIDAY, Oct. 25, 2024 (HealthDay News) -- As the popularity of GLP-1 meds like Wegovy and ...

Taking a GLP-1 receptor agonist was associated with a lower risk for cirrhosis and related complications in patients with metabolic dysfunction–associated steatotic liver disease and diabetes. For ...